GILD
Gilead Sciences IncBiological Products, (No Diagnostic Substances)
$150.11updated Sep 19, 2026
Congressional trading profile for Gilead Sciences Inc (GILD), covering 17 disclosed transactions by 9 lawmakers.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Total Trades
17
Politicians Trading
9
Last Traded
Aug 10, 2026
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ro KhannaD | Sep 4, 2026 | Aug 10, 2026 | Sell | $1,001 - $15,000 | +12.81% |
| Ro KhannaD | Aug 7, 2026 | Jul 7, 2026 | Sell | $1,001 - $15,000 | +10.08% |
| Val T. HoyleD | Oct 10, 2025 | Sep 23, 2025 | Sell | $1,001 - $15,000 | +31.22% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 - $50,000 | +44.59% |
| Josh GottheimerD | Jun 11, 2025 | May 14, 2025 | Sell | $1,001 - $15,000 | +52.58% |
| John BoozmanR | May 14, 2025 | Apr 16, 2025 | Sell | $1,001 - $15,000 | +43.13% |